Zealand Pharma As Stock Buy Hold or Sell Recommendation
ZLDPF Stock | USD 101.61 0.64 0.63% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Zealand Pharma AS is 'Strong Sell'. Macroaxis provides Zealand Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ZLDPF positions.
Check out Zealand Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Zealand and provide practical buy, sell, or hold advice based on investors' constraints. Zealand Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Zealand |
Execute Zealand Pharma Buy or Sell Advice
The Zealand recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Zealand Pharma AS. Macroaxis does not own or have any residual interests in Zealand Pharma AS or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Zealand Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Zealand Pharma Trading Alerts and Improvement Suggestions
Zealand Pharma AS generated a negative expected return over the last 90 days | |
Zealand Pharma AS has high historical volatility and very poor performance | |
The company reported the revenue of 292.57 M. Net Loss for the year was (1.02 B) with profit before overhead, payroll, taxes, and interest of 173.75 M. | |
Zealand Pharma AS has accumulated about 864.44 M in cash with (1.21 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.68. | |
Roughly 56.0% of the company outstanding shares are owned by institutional investors |
Zealand Pharma Returns Distribution Density
The distribution of Zealand Pharma's historical returns is an attempt to chart the uncertainty of Zealand Pharma's future price movements. The chart of the probability distribution of Zealand Pharma daily returns describes the distribution of returns around its average expected value. We use Zealand Pharma AS price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Zealand Pharma returns is essential to provide solid investment advice for Zealand Pharma.
Mean Return | -0.3 | Value At Risk | -5.3 | Potential Upside | 4.14 | Standard Deviation | 3.02 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Zealand Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Zealand Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Zealand Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Zealand Pharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Zealand pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.36 | |
β | Beta against Dow Jones | 0.46 | |
σ | Overall volatility | 3.09 | |
Ir | Information ratio | -0.14 |
Zealand Pharma Volatility Alert
Zealand Pharma AS exhibits very low volatility with skewness of -0.67 and kurtosis of 2.04. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Zealand Pharma's pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Zealand Pharma's pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Zealand Pharma Fundamentals Vs Peers
Comparing Zealand Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Zealand Pharma's direct or indirect competition across all of the common fundamentals between Zealand Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Zealand Pharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Zealand Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Zealand Pharma by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare Zealand Pharma to competition |
Fundamentals | Zealand Pharma | Peer Average |
Return On Equity | -1.44 | -0.31 |
Return On Asset | -0.48 | -0.14 |
Operating Margin | (3.82) % | (5.51) % |
Current Valuation | 1.45 B | 16.62 B |
Shares Outstanding | 51.28 M | 571.82 M |
Shares Owned By Insiders | 0.07 % | 10.09 % |
Shares Owned By Institutions | 56.21 % | 39.21 % |
Price To Earning | 4.03 X | 28.72 X |
Price To Book | 27.79 X | 9.51 X |
Price To Sales | 5.19 X | 11.42 X |
Revenue | 292.57 M | 9.43 B |
Gross Profit | 173.75 M | 27.38 B |
EBITDA | (982.6 M) | 3.9 B |
Net Income | (1.02 B) | 570.98 M |
Cash And Equivalents | 864.44 M | 2.7 B |
Cash Per Share | 18.68 X | 5.01 X |
Total Debt | 647.91 M | 5.32 B |
Debt To Equity | 0.96 % | 48.70 % |
Current Ratio | 3.83 X | 2.16 X |
Book Value Per Share | 7.91 X | 1.93 K |
Cash Flow From Operations | (1.21 B) | 971.22 M |
Earnings Per Share | (3.26) X | 3.12 X |
Target Price | 22.4 | |
Number Of Employees | 203 | 18.84 K |
Beta | 0.95 | -0.15 |
Market Capitalization | 1.57 B | 19.03 B |
Total Asset | 2.07 B | 29.47 B |
Retained Earnings | (1.24 B) | 9.33 B |
Working Capital | 356 M | 1.48 B |
Current Asset | 408 M | 9.34 B |
Current Liabilities | 52 M | 7.9 B |
Z Score | 1.2 | 8.72 |
Net Asset | 2.07 B |
Zealand Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Zealand . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Accumulation Distribution | 0.0087 | |||
Daily Balance Of Power | (0.72) | |||
Rate Of Daily Change | 0.99 | |||
Day Median Price | 102.06 | |||
Day Typical Price | 101.91 | |||
Market Facilitation Index | 0.89 | |||
Price Action Indicator | (0.77) | |||
Period Momentum Indicator | (0.64) |
About Zealand Pharma Buy or Sell Advice
When is the right time to buy or sell Zealand Pharma AS? Buying financial instruments such as Zealand Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Zealand Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aircraft Thematic Idea Now
Aircraft
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Aircraft theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aircraft Theme or any other thematic opportunities.
View All Next | Launch |
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.